Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of May 2015, specifically dated May 12, 2015. The registrant is a foreign private issuer based in Nes Ziona, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document serves solely to announce the pricing of the company's initial public offering (IPO).
Material Changes
The primary material event reported is the pricing of the company's U.S. initial public offering on May 11, 2015. The company offered 1,910,000 American Depositary Shares (ADSs), with each ADS representing 40 ordinary shares. Additionally, the offering included warrants to purchase 1,910,000 ADSs.
Guidance, Outlook, and Unusual Items
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the IPO pricing. The unusual item is the execution of the IPO itself, marking the company's entry into the public market.
Key Facts for Investor Verification
- Offering Price: $5.00 per ADS and $0.01 per warrant.
- Share Structure: Each ADS represents 40 ordinary shares.
- Total Volume: 1,910,000 ADSs and warrants to purchase 1,910,000 ADSs.
- Company Identity: Verify the registrant is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Source Document: Refer to the attached press release (Exhibit 99.1) for full details on the offering.